Skip to main content
. Author manuscript; available in PMC: 2017 Jan 4.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):313–322. doi: 10.1097/QAI.0000000000001093

Table 3. Effect of IPV exposure on each PrEP adherence outcome: univariate and multivariable results.

Pill count coverage <80% Tenofovir <40 ng/mL
Risk ratio (95% CI) p Adjusted* risk ratio (95% CI) p Risk ratio (95% CI) p Adjusted* risk ratio (95% CI) p
IPV in study, ≤ 3 months ago 1.28 (1.03–1.59) 0.03 1.49 (1.17–1.89) 0.001 1.41 (1.01–1.99) 0.05 1.51 (1.06–2.15) 0.02
IPV in study, >3 months ago 1.27 (1.05–1.54) 0.02 1.08 (0.86–1.36) 0.5 1.15 (0.91–1.45) 0.3 0.95 (0.73–1.24) 0.7
No IPV to date in study 1.00 -- 1.00 -- 1.00 -- 1.00 --
*

Adjusted for age (years), study site, time on study (days), and whether male partner reports outside sex partner